Antengene Corporation Limited (HK:6996) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Antengene Corporation Limited has announced that the Malaysian National Pharmaceutical Regulatory Agency approved a New Drug Application for XPOVIO® for two new indications in the treatment of multiple myeloma. This milestone reflects the company’s commitment to expanding its oncology portfolio and the potential for XPOVIO® to offer novel treatment options for patients. The company advises shareholders and potential investors to exercise caution when dealing in its shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.
